Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3202345 | 1.00 | PPARG (0.49) | PPARGRAB9AGAAHDAC6HDAC8 | |
| SCHEMBL3197128 | 0.86 | PPARG (0.53) | PPARGRAB9AGAAHDAC6HDAC8 | |
| SCHEMBL7607209 | 0.79 | CTSL (0.60) | PPARGRAB9AGAAACECTSL | |
| SCHEMBL3935801 | 0.79 | CTSL (0.60) | PPARGRAB9AGAAACECTSL | |
| SCHEMBL3927028 | 0.76 | CTSL (0.71) | PPARGRAB9AGAAACECTSL | |
| SCHEMBL28790851 | 0.76 | CTSL (0.71) | PPARGRAB9AGAAACECTSL | |
| SCHEMBL31156814 | 0.75 | GAA (0.65) | PPARGRAB9AGAAACECTSL | |
| SCHEMBL30241534 | 0.73 | HTR6 (0.66) | HDAC6HDAC8HDAC1HDAC2HDAC3 | |
| SCHEMBL2769024 | 0.73 | HTR6 (0.66) | HDAC6HDAC8HDAC1HDAC2HDAC3 | |
| SCHEMBL3193347 | 0.73 | CA2 (0.49) | PPARGNTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137363-A1 | Substituted Indoles And Methods Of Their Use | WYETH LLC (US) | 2010-06-03 | — | — | US | disclosed |
| US-7683091-B2 | Substituted indoles and methods of their use | WYETH (US) | 2010-03-23 | — | — | US | disclosed |
| CN-101263115-A | Substituted indoles and use thereof | WYETH CORP (US) | 2008-09-10 | — | — | CN | disclosed |
| EP-1919866-A2 | SUBSTITUTED INDOLES AND USE THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2008-05-14 | — | — | EP | disclosed |
| US-20070043101-A1 | Substituted indoles and methods of their use | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2007022321-A2 | SUBSTITUTED INDOLES AND USE THEREOF | WYETH (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043101-A1 | Substituted indoles and methods of their use | INMT, AANAT, IDO2 | PPARG 3579/4885RAB9A 3251/4885GAA 3470/4885 |
| US-20100137363-A1 | Substituted Indoles And Methods Of Their Use | INMT, AANAT, IDO2 | PPARG 3579/4885RAB9A 3251/4885GAA 3470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.